通过PKN2的Ubiquitination,TRIM40驱动病态心脏缩和心脏衰竭
Risheng Zhao1, Xiaoli Cui1, Huizhu Du2
1Department of Pharmacology, College of Pharmacy, Beihua University, Jilin, Jilin, P. R. China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|January 23, 2026
概括
三方动因含有40 (TRIM40) 通过激活PKN2.2驱动病态心脏缩. 抑制TRIM40可能为心力衰竭 (HF) 提供一种新的治疗策略.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 病态心脏缩是心力衰竭 (HF) 的重要危险因素.
- 了解心脏缩背后的分子机制对于开发有效治疗方法至关重要.
- 在调节细胞过程中,包括心脏重塑过程中,E3泛素连接酶起着至关重要的作用.
研究的目的:
- 为了研究E3泛素连酶三方基因含有40 (TRIM40) 在病理性心脏缩的发展中的作用.
- 阐明TRIM40影响心脏缩的分子机制.
主要方法:
- 使用TRIM40淘汰,心脏特异性淘汰和过度表达的小鼠模型.
- 使用血管素II (Ang II) 输液和横向大动脉收缩 (TAC) 诱导的病理性心脏缩.
- 研究了TRIM40和PKN2之间的相互作用,包括无处化和酸化事件.
主要成果:
- 在过度缩的心脏中,TRIM40表达升高.
- TRIM40缺乏减轻了心脏缩和功能障碍,而过度表达加剧了病态重塑.
- TRIM40结合和K63结合的普基酸PKN2,增强其在Ser815的酸化,并激活下游信号通路.
- 药理上抑制PKN2改善了TRIM40过度表达引起的心脏重塑.
结论:
- 通过PKN2.2的无处不在和激活,TRIM40促进心脏缩和功能障碍.
- TRIM40代表了缓解心脏缩和预防心力衰竭的潜在治疗标.
相关概念视频
01:29Heart Failure II: Pathophysiology
798
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
798
01:17Pathophysiology of Heart Failure
3.1K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.1K
01:27Heart Failure I: Introduction
737
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
737
01:22Heart Failure VI: Adjunct Therapies
280
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
280
01:22Heart Failure Drugs: Diuretics
830
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
830
01:30Heart Failure V: Medical Management
232
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
232